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Abstract
Background: Myofascial pain syndrome (MPS) of the shoulder girdle and cervical region is a common musculoskeletal
problem that is often chronic or recurrent. Physical therapy (PT) and lidocaine injections (LI) are two treatments with
demonstrated effectiveness compared to a control group, however little is known about their combined value. The
objective of this study was to determine whether LI into trigger points combined with a PT program would be more
effective than each separate treatment alone in improving pain, function, and quality of life in a group of patients with
MPS of the shoulder girdle and cervical region.
Methods: A single-blind, randomized, controlled clinical trial (RCT) was conducted with three parallel groups in the
Departments of Physical Medicine and Rehabilitation of two urban hospitals in Medellin, Colombia. One hundred and
twenty seven patients with shoulder girdle MPS for more than 6 weeks and pain greater than 40 mm on the visual
analog scale (VAS) were assigned to 1 of 3 intervention groups: PT, LI, or the combination of both (PT + LI). The primary
outcome was VAS pain rating at 1-month post-treatment. The secondary outcomes included VAS pain rating at
3 months, and, at both 1 and 3 months post-treatment: (a) function, evaluated by hand-back maneuver and the
hand-mouth maneuver, (b) quality of life, as measured by sub-scales of the Short Form – 36 (SF-36), and (c)
depressive symptoms, as measured by the Patient Health Questionnaire – 9 (PHQ-9). Independent t-tests were
used to compare outcomes between groups at 1 month and 3 months post-treatment.
Results: In the per protocol analysis, there were no significant intergroup differences in VAS at 1 month PT + LI,
40.8 [25.3] vs. PT, 37.8 [21.9], p = 0.560 and vs. LI, 44.2 [24.9], p = 0.545. There were also no differences between
groups on secondary outcomes except that the PT and PT + LI groups had higher right upper limb hand-back
maneuver scores compared to the LI alone group at both 1 and 3 months (p = 0.013 and p = 0.016 respectively).
Conclusions: The results of this RCT showed that no differences in pain ratings were observed between the
individual treatments (PT or LI) compared to the combined treatment of PT and LI. In general, no difference in
primary or secondary outcomes was observed between treatments.
Trial registration: NTC01250184 November 27, 2010.
Keywords: Myofascial pain, Trigger points, Lidocaine injection, Physical therapy
* Correspondence: luzh.lugo@gmail.com
1Health Rehabilitation Group and Academic Group of Clinical Epidemiology,
University of Antioquia, Carrera 53 # 61-30, Medellín, Antioquia, Colombia,
South America
Full list of author information is available at the end of the article
© 2016 Lugo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lugo et al. BMC Musculoskeletal Disorders  (2016) 17:101 
DOI 10.1186/s12891-016-0949-3
Background
Myofascial pain syndrome (MPS) is a major cause of
chronic musculoskeletal pain and is characterized by the
presence of hypersensitive areas and myofascial trigger
points (MTrPs) in a muscle or its fascia that, when pal-
pated, may trigger a characteristic referred pain, tender-
ness and autonomic phenomena [1].
The prevalence of MPS varies from 21 % in orthopedic
clinics to 30 % in general practice, and between 55 and
95 % in specialized pain management centers [2, 3]. Some
studies suggest that latent MTrPs may be present in be-
tween 45 and 55 % of the muscles of the shoulder girdle
and between 5 and 55 % of the muscles of the pelvic girdle
of asymptomatic young adults [4]. Myofascial pain syn-
drome can be acute or chronic and primary or secondary.
MPS may be associated with radiculopathy, nerve entrap-
ments, metabolic and nutritional disorders, biomechanical
imbalance, and/or physical deconditioning [5].
The concept of MTrPs can be considered to be contro-
versial because some researchers argue that the key
phenomenon of muscle tenderness demands a robust
plausible explanation based on neurobiology [6]. In re-
sponse, other researchers purport this argument is not
sufficient to invalidate the integrated trigger point hypoth-
esis [7]. They insist that numerous physiological mecha-
nisms have been proposed. The integrated trigger point
hypothesis is the most accepted physiological model to ex-
plain these phenomena. This model explains how abnor-
mal depolarization of the post-junctional membrane of
motor endplates causes a localized hypoxic energy crisis
associated with sensory and autonomic reflex arcs that are
sustained by complex sensitization mechanisms [8, 9].
Biochemical abnormalities have been described to explain
this neuromuscular dysfunction consisting of motor and
sensory abnormalities involving both the peripheral and
central nervous system [10, 11]. A more recent hypothesis
suggests that MTrPs are caused by a nociception-induced
central nervous system disorder which is centrally main-
tained by α-motoneuron plateau depolarization, but un-
fortunately experimental evidence for this hypothesis is
still lacking [12, 13]. Furthermore, it is possible that some
of the mechanisms proposed to explain chronic non-
specific low back pain could be considered to apply to
chronic myofascial pain in the cervical region [14]. For ex-
ample, psychosocial factors may make acute pain become
chronic and, indeed, patients with MPS have been found
to have higher rates of anxiety and depression [15].
The diagnosis of MPS can also be considered controver-
sial. Some researchers suggest that focal areas of muscle
pain defined as associated with MTrPs cannot be reliably
identified. Although inter-observer variability does exist, re-
search shows that, after implementing a training program
to ensure systematic physical examinations, an appropriate
percentage of agreement between different examiners can
be achieved, especially when palpating the trapezius,
gluteus maximus and quadratus lumborum trigger points
[16–18]. Various methods have been utilized to achieve
better reproducibility of the diagnosis of MPS. For in-
stance, Simons and Travell’s method takes into account
the existence of MTrPs during muscle palpation, a charac-
teristic pattern of referred pain, the display of local
response contractions or twitches, and joint mobility re-
striction in compromised muscles. Functional limitation is
evaluated by means of specific movements such as the
hand-back (patient’s ability to touch the lower angle of the
contralateral scapula) and the hand-mouth (patient’s abil-
ity to exceed the contralateral labial commissure when
passing the hand behind the head) maneuvers [1, 19].
There are many different treatments for MPS. Non-
invasive treatments include therapeutic exercise, ultra-
sound, and massage and stretching the affected muscle
with aerosolized fluoromethane. A systematic review of 21
randomized controlled trials (RCTs) [20] showed moder-
ate quality evidence according to the GRADE (Grading of
Recommendations Assessment, Development, and Evalu-
ation) system [21] that stretching and strengthening are
effective for improving pain, function, and perception of
improvement in chronic neck pain in the early and inter-
mediate follow-up periods. In another systematic review
of 26 RCTs, exercise proved to be effective for improving
pain and function in rotator cuff disease [22]. A meta-
analysis synthesizing the evidence from 12 studies indi-
cated that high-quality therapeutic massage was effective
for neck and shoulder pain, but did not improve function
[23]. No interventions have demonstrated the effective-
ness of capsaicin patches [24], except those with lidocaine,
which improved pain over a 1-month period [25].
Invasive treatments have also been used to treat MPS,
including dry-needling or medications, such as local anes-
thetics, corticosteroids, or botulinum toxin [5]. Dry need-
ling has proven effective, with improvement depending on
the technique used [26]. Lidocaine and bupivacaine injec-
tions were found to be more effective than placebo injec-
tions for improving pain [25, 26], with the needle size
used (21, 23, and 25 gauge) unrelated to treatment effect-
iveness [27]. Studies of non-steroidal anti-inflammatory
drugs (NSAIDs), psychotropic medications, steroid injec-
tions, and muscle relaxants have been conducted with
limited evidence and unclear benefits [28, 29].
Methods
Aim
Because of the lack of research examining which treat-
ments, or combination of treatments, are more effective
for MPS, the objective of the present study was to deter-
mine whether lidocaine injection (LI) into MTrPs com-
bined with a physical therapy (PT) program was more
effective than each separate treatment alone on the
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outcomes of pain, function, and quality of life in a group
of patients with MPS of the shoulder girdle and cervical
region.
Study design and setting
A single blind, randomized, controlled clinical trial
(RCT) was conducted in two different city hospitals in
Medellín, Colombia (IPS Universitaria and Clínica Las
Americas) between January 2009 and October 2011. Ap-
proval was obtained from the Ethics Committee of the
University of Antioquia.
Participants
Using the patient databases of two general and specialized
medical institutions, 762 patients were identified to have
non-specific myalgia or muscle disorders diagnoses. These
diagnoses were chosen because the International Classifi-
cation of Disease Version 10 (ICD-10) does not have a
specific code for MPS. The inclusion/exclusion criteria
were: 1. To be older than 18 years of age. 2. To have
MTrPs in one or more of the following muscles: the tra-
pezius, the infraspinatus, and/or the levator scapulae (cer-
vical portion), diagnosed by neck or shoulder pain, which
may or may not be accompanied by the typical pattern of
referred pain in the compromised muscle. 3. To have had
neck or shoulder pain over the prior 6 weeks (because
there is controversy concerning the cutoff for acute pain
as either 4 or 6 weeks, 6 weeks was chosen). 4. To have a
minimum pain score of 40 mm on the visual analog scale
(VAS). 5. To not have moderately severe depression, as in-
dicated by a score of higher than 15 on the Patient Health
Questionnaire (PHQ-9) measure of depressive symptoms,
and/or presence of a psychiatric or bipolar affective dis-
order. 6. To not have comorbid conditions such as Fibro-
myalgia according to the criteria of American College of
Rheumatology [30, 31], polyneuropathy, entrapment syn-
dromes and radiculopathies of the upper limb, presence of
inflammatory or infectious diseases that were not being
medically treated, history of whiplash, or allergy to local
anesthetics. 7. To not be receiving treatment or have re-
ceived treatment in the last month. 8. To not be consum-
ing painkillers or continuously using anti-inflammatory
medications.
A nurse with 10 years of research experience conducted
a phone screen of 762 patients to assess the inclusion and
exclusion criteria. If the patients were older than 18 years
of age, had neck pain or shoulder girdle pain, and had not
received treatment in the last month, the patient was
given an appointment for a medical evaluation. Two hun-
dred and sixty seven patients were excluded during the
phone screen for having a non-MPS diagnosis, MPS of
less than 6 weeks duration, or in current treatment for
MPS. Four hundred and ninety-five patients were given an
appointment at the hospital for a clinical assessment. At
the appointment, two medical physiatrists (LHL and JAP)
with over 10 years of research experience performed a
clinical evaluation of the MPS patients and reviewed their
medical history in order to verify inclusion and exclusion
criteria. At this stage, 360 patients were excluded due to:
moderately severe depression with a score higher than 15
on the Patient Health Questionnaire (PHQ-9) measure of
depressive symptoms and/or presence of psychotic or bipo-
lar affective disorder and/or existence of comorbid condi-
tions listed in the inclusion/exclusion criteria. The selected
muscles (according to their anatomical location) were care-
fully palpated using a gel and manual detection of trigger
points. Patients were observed and asked if they experi-
enced pain. If they responded affirmatively, they were asked
if that pain was located in the same palpation point or in a
different point. In addition, patients were also asked to indi-
cate the location of the pain on a form with drawings of the
muscles and their trigger points.
All eligible patients were invited to participate in the
study. The patients were informed of the study before
the first assessment and signed a written, informed con-
sent statement.
The final sample consisted of 135 patients, with 45 pa-
tients were randomly allocated to each of the three
groups: Physical Therapy (PT) + Local Injection (LI), PT
only, and LI only. After randomization, 2 patients in the
PT + LI group were excluded (one of them with VAS <
40 mm and the other with PHQ-9 > 15), 4 patients in the
PT group (for having VAS < 40 mm), and 2 patients in the
LI group (one because of breast cancer and the other due
to VAS < 40 and PHQ-9 > 15) (Fig. 1).
Interventions
Patients were randomly assigned to 1 of the following 3
groups: group 1, the PT + LI group, included 41 patients
who underwent a PT program and trigger point LI with
0.5 % lidocaine without epinephrine; group 2, the PT
group, included 43 patients who underwent the PT pro-
gram alone; and group 3, the LI group, included 43 pa-
tients who underwent trigger point LIs with 0.5 %
lidocaine without epinephrine alone.
The PT intervention included 12 sessions of PT lasting
1 h, 3 times per week, for 4 weeks. The average number
of PT sessions attended in the PT + IL group was 8.7
(SD: 4.7), while the average number of PT session
attended in the PT group was 7.4 (SD: 5.2). The physical
therapy intervention in both groups (PT and PT + LI) at
each session consisted of 10 min of hot pack and ultra-
sound with 0.8 W/cm2 and 1 Hz. Then the physical
therapist deactivated active MTrPs via manual compres-
sion for 10 min. The deactivation procedure required
the physical therapist to apply gentle, gradually increas-
ing pressure on the MTrPs until the finger encountered
a definite increase in tissue resistance. The pressure was
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maintained until the therapist sensed relief of tension
under the palpating finger or the patient experienced a
considerable decline in pain. This technique was com-
bined with other manual techniques, such as deep strok-
ing (pressure directed along the length of the taut band)
or strumming (pressure applied perpendicularly across
the muscle fibers). Then muscle-stretching and strength-
ening exercises were performed for the cervical and
shoulder girdle and specific for trapezius, infraspinatus,
and the levator scapulae muscles for a total of 30 min,
followed by exercises to improve joint range of motion
for 10 min more. This was protocol was standardized by
LHL based on various publications and recommenda-
tions [20, 22, 23] and conducted by one of three physio-
therapists with more than 5 years of experience.
The LI intervention consisted of an injection of 0.5 %
lidocaine without epinephrine into MTrPs. The injections
were given as follows: once the MTrP was located, anti-
sepsis was performed using 70 % alcohol, the MTrP was
located between two fingers, and a 1-2 cm sterile needle
with a thickness of 25 or 26 gauge was inserted into the
MTrP at an angle of 30° with respect to the skin. To en-
sure that the needle was not in a blood vessel, the needle
was aspirated before injecting a small amount (0.2 ml) of
0.5 % lidocaine. Then, the needle was withdrawn to the
subcutaneous tissue and redirected superiorly, inferiorly,
laterally and medially, repeating the process described
above [5, 27]. Pressure was applied to the injected area to
promote hemostasis, and adhesive tape was used to
cover the skin. Patients were advised to gradually re-
turn to their activities, avoiding strenuous activities for
the first 3 to 4 days after the injection. On the day that
patients were randomly assigned to the PT + LI group,
they received the LI intervention and 2 to 3 days later,
they began the PT treatment.
If there was no improvement in pain, all patients were
allowed to use analgesics, such as acetaminophen 2-3g/
day and/or ibuprofen 1.2 to 2.4 g/day.
Outcomes
The primary outcome was pain at 4 weeks after the day
of initial evaluation. Pain was measured using a VAS
with a score of 0–100, where 100 is the value represent-
ing the highest degree of pain. Successful treatment was
defined as a reduction in pain of at least 20 % of the pre-
vious score on the VAS after 4 weeks of the initial
Fig. 1 Flow diagram of participants
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evaluation, or a reduction of 14 mm on the VAS. The
VAS is a reliable pain assessment measure that has been
validated previously [29]. At each time of assessment,
patients were asked about their pain in the last 24 h.
The following secondary outcomes were assessed at 1
and 3 months post-treatment: quality of life (QoL), de-
pressive symptoms, and function. QoL dimensions, in-
cluding bodily pain were assessed via the Short Form-36
(SF-36). The SF-36 consists of 36 items addressing the
patient’s perception of their QoL in the following eight
domains: physical function (PF), role limitations due to
physical problems (RP), bodily pain (BP), general health
(GH), vitality (VT), social functioning (SF), role limita-
tions due to emotional problems (RE), and mental health
(MH), and one item describing change in health. Sub-
scale scores range from 0 to 100, with 100 as the best,
most positive QoL in that area and 0 is the worst, this
scale has been validated in Colombia [32]. Depressive
symptoms were measured using the Colombian version
of the Patient Health Questionnaire – 9 (PHQ-9). The
PHQ-9 was developed from the Primary Care Evaluation
of Mental Disorders (PRIME-MD) and evaluates each of
the nine criteria for major depression according to the
Diagnostic and Statistical Manual of Mental Disorders –
IV (DSM-IV). The self-report instrument asks individ-
uals how much they had been bothered by any of the
nine problems over the prior two weeks. Items are
scored from 0 (not at all) to 3 (nearly every day). Items
are summed and the total score (from 0 to 27) repre-
sents the severity of depressive symptoms [33]. The Co-
lombian version of the scale was used and is available by
Pfizer. Function was evaluated using the hand-back
maneuver (patient’s ability to touch the lower angle of
the contralateral scapula) and the hand-mouth maneuver
(patient’s ability to exceed the contralateral labial com-
missure when passing the hand behind the head) [1, 19].
Higher scores indicate better function. A final secondary
outcome was pain rating at 3 months post-treatment
measured using a VAS with a score of 0–100, where 100
is the value representing the highest degree of pain.
Study procedures
Randomization
The randomization process was performed using per-
muted blocks (with RALLOCK software) to avoid an im-
balance in the number of patients in each group and to
leave open the possibility of an interim analysis, if neces-
sary. This process was performed by an investigator
(HIG) who had no contact with the patients. The alloca-
tions to each treatment were placed in consecutive
sealed, opaque envelopes. They were kept in the research
headquarters and were taken to the site according to the
number of patients referred.
At the initial appointment, two Physical Medicine &
Rehabilitation (PM&R) physician researchers (LHL, JAP)
with over 5 years of experience in the treatment of MPS
performed the clinical evaluation and noted the relevant
information on the patient forms. A nurse then adminis-
tered the VAS, SF-36, and PHQ-9 questionnaires, and
evaluated the participant’s function. In addition, patients
were asked if, over the prior month, they had experi-
enced stressful situations and/or sleep disturbances.
They were also asked for their occupation to assess the
need to engage in continuous positions. The participant
subsequently opened an opaque, sealed and sequentially
numbered envelope to discover the group to which they
were assigned. If the patient was in one of the two
groups receiving injections, the physician researcher
(LHL, JAP) immediately administered the injection per
the intervention procedures described above. Those par-
ticipants assigned to 1of the 2 PT groups received the
dates and times of 12 appointments with a selected and
trained physiotherapist. Outcomes were assessed at
baseline and at 4 and 12 weeks and were evaluated by a
trained nurse (RR) with more than 10 years of experi-
ence in the application of the instruments. The nurse
was independent of the researchers and blind to the
intervention.
Single blinding
The PM&R physicians who evaluated the patients at
baseline and the nurse who assessed the patients at base-
line and follow-up were blinded to treatment allocation.
Physicians who performed the MTrPs injection did not
participate in the evaluation of primary and secondary
outcomes. Physical therapists who conducted the thera-
peutic exercise program did not participate in the evalu-
ation of primary and secondary outcomes.
Statistical analysis
Sample size
Sample size was calculated with the software “Sample
Size from Javeriana University” [34], with the following
parameters according to the literature review: type I
error = 0.05, type II error = 0.2 (80 % power), number of
measurements before randomization = 1, number of
measurements performed after randomization = 2, cor-
relation between measurements = 0.6, and clinically sig-
nificant difference 0.35, or a reduction in pain of at least
20 % for an n of 45 patients per group [35].
Data analyses
The baseline data of each group prior to the intervention
was described using frequency distributions and averages
with standard deviations. The normality of the distribu-
tions of the quantitative variables was tested using the
Kolmogorov-Smirnov test. Comparisons of baseline data
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were made between all three groups (PT+ IL vs. PT vs.
IL at baseline using Kruskal-Wallis tests or chi square
tests). Independent t-tests were used to comparison of
outcomes between groups at 1 month and 3 months
post-treatment. The baseline characteristics of the
groups before starting the intervention and after
randomization are shown in Table 1. Missing patients
were not included in the data analysis. A per-protocol
analysis was conducted.
All statistical analyses were conducted using an alpha
of 0.05, so that a p value of less than 0.05 was consid-
ered to be statistically significant. Data analyses were
performed using software SPSS® 18 (IBM, Armonk,
New York).
Table 1 Base-line characteristics of the patients
Characteristics Physical therapy + local injection Physical therapy Local injection
(n = 41) (n = 43) (n = 43) p
Sex (%)
Female 35 (85.4) 36 (83.7) 33 (76.7) 0.55*
Age (Mean, SE) 37.2 (11.1) 42.6 (9.7) 37.7 (11.8) 0.081**
Residence (%)
Medellín 32 (78.0) 35 (81.4) 35 (81.4)
Other municipalities 9 (22.0) 8 (18.6) 8 (18.6) 0.906*
Concomitant factors (%)
Stress 34 (82.9) 29 (67.4) 30 (69.8) 0.227*
Sleeplessness 24 (58.5) 18 (41.9) 23 (53.5) 0.290*
Longer positions 27 (65.9) 34 (79.1) 29 (67.4) 0.342*
Muscles with trigger point (%)
Trapezius muscle 37 (90.2) 42 (97.7) 39 (90.7) 0.326*
Levator scapulae 31 (75.6) 27 (62.8) 26 (60.5) 0.290*
Infraspinatus
muscle 12 (29.3) 12 (27.9) 13 (31.0) 0.953*
Physical examination (%)
Alteration sensitive 8 (19.5) 7 (16.3) 8 (18.6) 0.924*
Referred pain 22 (53.7) 36 (83.7) 23 (53.5) 0.004*
Local twitch response 29 (70.7) 26 (61.9) 22 (51.2) 0.183*
Visual Analogue
Scale for Pain (Mean, SD) 63.5 (13.9) 68.7 (17.0) 64.2 (16.2) 0.340**
PHQ 9 (Mean, SD) 5.6 (3.2) 5.9 (4.2) 5.6 (3.5) 0.995 **
Quality of life SF-36 (Mean, SD)
Bodily pain (BP) 38.8 (14.4) 35.2 (14.3) 38.5 (16.4) 0.642**
Role-emotional (RE) 66.4 (35.0) 75.8 (38.7) 67.2 (36.8) 0.273**
Role-physical (RP) 51.2 (40.0) 51.1 (37.7) 42.4 (37.6) 0.498**
Physical functioning (PF) 79.5 (17.8) 72.5 (20.5) 81.7 (11.9) 0.095**
Social function (SF) 69.5 (22.0) 68.0 (26.6) 71.8 (23.6) 0.799**
General health (GH) 67.4 (18.3) 57.3 (21.9) 70.7 (15.4) 0.01**
Mental health (MH 67.8 (14.2) 65.5 (18.9) 67.4 (17.5) 0.805**
Vitality (VT) 54.2 (13.9) 54.7 (19.2) 60.7 (19.3) 0.181**
*(Chi2)
**Kruskal-Wallis
Patient Health Questionnaire (PHQ-9), Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents
the severity of depressive symptoms. Higher scores on the Visual Analogue Scale for Pain (VAS-P) indicate more pain, with a maximum of 100 (range, 0–100).
Short Form Health Survey, the SF-36 with 8 sub-scales: BP bodily pain, RE role limitations as a result of emotional problems, RP role limitations as a result of physical
problems, PF physical functioning, SF social functioning, GH general health perception, MH general mental health, VT vitality (the frequency of feeling full of energy vs
feeling tired). Total sub-scale scores range from 0–100 with higher scores indicating better quality of life
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Results
Data was analyzed from 127 patients: 43 patients in the
PT + LI group, 41 in the PT group, and 43 in the LI
group. See the flowchart in Fig. 1.
A total of 92 % the of participants received public health
care assistance and 10 % had hypertension. These propor-
tions were similar among groups. Additional baseline
characteristics of the three groups are shown in Table 1.
Groups were similar in socio-demographic and clinical
characteristics - 96 % had active trigger points and 4 % la-
tent MTrPs at the time of examination, and 65 % of these
experienced a characteristic pattern of referred pain. A
significantly larger proportion of the PT group (83.7 %)
had referred pain compared to the other two groups (53 %
each one; p < 0.01). Functional limitations presented by
the patients were as follows: 15 % could not lower hori-
zontal objects, 14 % had difficulty combing their hair, 9 %
had difficulty dressing, and 6.5 % had difficulty bathing.
These proportions of patients experiencing functional lim-
itations were similar across the three groups.
In terms of the limitation in range of motion, the head
tilt to the left was the most limited (31 %) followed by the
right slant (27 %), rotations to the left (19 %) and right
(14 %), flexion (7.3 %) and finally extension (5.6 %). There
were no significant differences between the groups in
range of motion.
At baseline, patients in each group had similar VAS
pain scores, similar PHQ-9 scores as a measure of de-
pressive symptoms, and similar QoL on the all the di-
mensions of the SF-36 except in the general health
domain in which those in the PT group reported signifi-
cantly worse general health QoL compared to the PT +
LI and LI groups [57.3 (21.9) vs. 67.4 (18.3) and 70.7
(15.4), respectively, p = 0.01].
Primary outcome
As shown in Table 2, there were no statistically signifi-
cant differences in pain ratings at 1 month as measured
by the VAS between the PT + LI group [40.8 (25.3)] and
the PT group [37.8 (21.9), p = 0.56] or the LI group [44.2
(24.9), p = 0.545].
Secondary outcomes
At 1 month, there were also no significant differences
between groups in their PHQ-9 depression scores or on
any of the quality of life dimensions measured by the
SF-36 sub-scales (see Table 2). Individual SF-36 item dif-
ferences between groups were analyzed. The only item
in which there was a significant difference was the
change in health item in which the PT + LI group had
significantly higher QoL [70.0 (18.1)] compared to the
PT group [60.93 (18.5), p = 0.03]. The LI group mean on
this item was 67.8 (16.1) and not significantly different
from the PT + LI group mean (p = 0.49).
The 3-month outcomes are shown in Table 3. There
were no statistically significant differences between groups
in VAS pain scores, PHQ-9 depression scores, or SF-36
quality of life sub-scales.
Regarding function, at 1 month and 3 months, the PT
and PT + LI groups showed higher right upper limb
hand-back maneuver scores compared to the LI alone
group (p = 0.013 and p = 0.016 respectively). The left
upper limb hand-back maneuver and right and left
Table 2 Primary and secondary outcomes in the Physical Therapy and Local injection, Physical Therapy + Local injection, Physical
Therapy and Local injection at 1 month in patients with myofascial pain syndrome
Outcomes Physical therapy + local injection (n = 41) Physical therapy (n = 43) P value* Local injection (n = 43) P value*
Visual Analogue Scale for Pain
(Mean, SD)
40.8 (25.3) 37.8 (21.9) 0.560 44.2 (24.9) 0.545
PHQ 9 (Mean, SD) 4.33 (3.65) 4.43 (4.073) 0.904 4.44 (3.03) 0.879
Quality of life SF-36 (Mean, SD)
Bodily pain (BP) 55.3 (18.4) 57.12 (20.70) 0.89 51.78 (15.70) 0.29
Role-emotional (RE) 78.2 (35.1) 85.95 (27.58) 0.31 78.76 (33.24) 0.94
Role-physical (RP) 73.1 (40.5) 73.84 (34.48) 0.56 74.39 (33.30) 0.58
Physical functioning (PF) 86.8 (13.2) 82.79 (15.52) 0.21 86.83 (11.55) 0.72
Social function (SF) 79.2 (20.7) 81.51 (22.83) 0.38 78.15 (20.44) 0.78
General health (GH) 72.1 (16.7) 65.70 (20.16) 0.12 73.54 (13.43) 0.99
Mental health (MH 73.2 (16.6) 70.05 (19.82) 0.46 69.95 (17.57) 0.34
Vitality (VT) 61.3 (16.0) 59.88 (19.83) 0.66 62.56 (17.32) 0.95
*T-test to compare differences between groups at month
Patient Health Questionnaire (PHQ-9), Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents
the severity of depressive symptoms. Higher scores on the Visual Analogue Scale for Pain (VAS-P) indicate more pain, with a maximum of 100 (range, 0–100). Short
Form Health Survey, the SF-36, with 8 sub-scales: BP bodily pain, RE role limitations as a result of- emotional problems, RP role limitations as a result of physical problems,
PF physical functioning, SF social functioning, GH general health perception, MH general mental health, VT vitality (the frequency of feeling full of energy vs. feeling
tired). SF social functioning, MH general mental health. Total sub-scale scores range from 0–100 with higher scores indicating better quality of life
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hand-mouth maneuvers were not significantly different
between groups.
Analgesic use and complications
There were no significant differences in analgesic use be-
tween groups (p = 0.10); 36.6 % of the PT + LI group used
took analgesics, while 53.0 % of the PT group and 51.2 %
of the LI group used these supplementary medications.
There were complications documented for six patients.
In the PT + LI group, four participants had localized he-
matomas. In the LI group, two participants had localized
hematomas and one participant had minimal bleeding.
In total, for the number of injections performed (n = 84)
the complication rate was 2.66 %. There were no com-
plications in the PT group.
Discussion
In this study, the efficacy and safety of two interventions,
PT and LI, were compared, alone vs. in combination, in
male and female patients over 18 years of age with
shoulder or neck pain of more than 6 weeks duration
and MTrPs of the trapezius, infraspinatus, and/or levator
scapulae (cervical portion). There were no statistically
significant differences between the combination group
and the individual treatment alone groups in VAS pain
ratings, PHQ-9 depression scores, or SF-36 QoL do-
mains at neither 1 nor 3 months.
There are no studies in the literature that evaluate head-
to-head whether lidocaine injection into MTrPs combined
with a PT program might be more effective than each sep-
arate treatment alone in improving pain, function, and
quality of life in patients with MPS of the shoulder girdle
and cervical region. However, in a recent Cochrane review
of treatments for chronic neck pain, moderate quality evi-
dence supports cervico-scapulothoracic and upper ex-
tremity strength and endurance exercises and combined
cervical, shoulder and scapulothoracic strengthening and
stretching exercises to improve pain and function [36].
The present study’s PT treatment incorporated similar PT
exercises, without homework exercises, and included pa-
tients with MTrPs in the infraspinatus muscle as well. In
this study, PT alone and in combination with LI showed
better right, but not left limb hand-back maneuver func-
tioning compared to LI injection alone. Several studies
have documented the effectiveness of PT exercises on
myofascial pain. For instance, an RCT of patients with
MTrPs in the upper trapezius found that employing differ-
ent manual techniques (such as ischemic compression,
stretching after ischemic compression, and passive
stretching) resulted in improved range of motion and pain
sensitivity; outcomes in this study were measured only at
24 h and 1 week, and other functional outcomes were not
evaluated [37]. In this study, PT treatment involved the
use of hot packs and ultrasound, manual compression,
deep stroking or strumming, and muscle-stretching and
strengthening exercises. These techniques were focused
on the cervical and shoulder girdle and specifically the tra-
pezius, infraspinatus, and the levator scapulae muscles.
Furthermore, the current study assessed longer term out-
comes at 1 and 3 months post-treatment, and the groups
receiving PT had significantly better right upper limb
hand-back maneuver function. However, left upper limb
Table 3 Secondary outcomes in the physical therapy and local injection, physical therapy + local injection, physical therapy and
local injection at 3 months in patients with myofascial pain syndrome
Outcomes Physical therapy + local injection (n = 41) Physical therapy (n = 43) P value Local injection (n = 43) P value*
Visual Analogue Scale for Pain
(Mean, SD)
21.6 (21.8) 28.2 (23.7) 0.192 28.8 (22.3) 0.141
PHQ 9 (Mean, SD) 3.98 (3.97) 4.12 (4.48) 0.877 3.16 (2.81) 0.284
Quality of life SF-36 (Mean, SD)
Bodily pain (BP) 66.58 (20.09) 65.66 (20.9) 0.69 61.19 (17.67) 0.16
Role-emotional (RE) 83.25 (32.11) 84.13 (32.95) 0.70 90.60 (21.15) 0.38
Role-physical (RP) 81.88 (30.48) 82.5 (31.11) 0.75 87.79 (22.07) 0.44
Physical functioning (PF) 87.75 (16.94) 89.13 (12.29) 0.56 90 (9.06) 0.41
Social function (SF) 82.6 (20.99) 83.05 (20.71) 0.88 83.28 (17.44) 0.87
General health (GH) 71.67 (17.26) 68.25 (22.37) 0.72 77.44 (12.50) 0.15
Mental health (MH 75.3 (16.79) 71.32 (17.86) 0.30 78.95 (14.03) 0.43
Vitality (VT) 63.38 (16.11) 61.95 (18.53) 0.77 69.64 (16.17) 0.20
*T-test to compare differences between groups at month
Patient Health Questionnaire (PHQ-9), Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents
the severity of depressive symptoms. Higher scores on the Visual Analogue Scale for Pain (VAS-P) indicate more pain, with a maximum of 100 (range, 0–100).
Short Form Health Survey, the SF-36 with eight sub-scales: BP bodily pain, RE role limitations as a result of- emotional problems, RP role limitations as a result of
physical problems, PF physical functioning, SF social functioning, GH general health perception, MH general mental health, VT vitality (the frequency of feeling full
of energy vs. feeling tired), SF social functioning, MH general mental health. Total sub-scale scores range from 0–100 with higher scores indicating better quality
of life
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function was not significantly different between groups, so
additional research on the value of PT focused on these
muscles in this patient group may be warranted. Another
study in patients with shoulder pain of more than
6 months with a MTrP average pain rating of 7.4 (3.6)
showed that a comprehensive PT treatment once a week
with manual TP compression, stretching, cold application,
and instructions for home exercises was more effective
than doing nothing to improve the function; this improve-
ment was demonstrated on the DASH (Disabilities of the
Arm, Shoulder, and Hand) and on pain measured via the
VAS at the time of the evaluation and in the final 7 days
of treatment [29]. The present study PT treatment incor-
porated similar PT exercises and also included patients
with MTrPs in the shoulder (infraspinatus muscle) but we
did not use the DASH Scale to measure function.
Massage, another technique incorporated into the PT
treatment group of the present study, has been shown to
be effective in reducing pain compared with inactive ther-
apies, such as usual care; however, massage alone has not
been found to be more effective than active therapies,
such as exercise [23]. In one study, massage was effective
for the relief of subacute and chronic neck pain, but only
in the short term [38]. In the present study, massage was
used, but only in combination with other PT techniques,
i.e., muscles involved were stretched and strengthened,
thus further study that isolates the effects of massage
alone on function or other outcomes may prove valuable.
Regarding lidocaine injections, in this study, using lido-
caine injections alone was found to be similarly effective
to lidocaine plus physical therapy. Similarly, in an RCT
conducted with a smaller sample size of 80 patients, both
dry needling and an injection of lidocaine improved pain
ratings, but there were no differences between the groups
[39]. In the present study, lidocaine was injected only one
time and it is possible that multiple injections over time
might lead to more improvement. One study showed that,
compared to placebo, a series of 5 lidocaine injections on
alternating days to the pericranial muscles significantly re-
duced both the frequency and severity of pain at 2, 4 and
6 months post treatment in MPS patients. [40] Additional
RCTs examining the intensity and frequency of the pro-
posed interventions, either alone or in combination, may
help guide clinicians in their treatment strategies.
In a systematic review of needling therapies in the
management of MTrP pain, the effect of MTrP injec-
tions was independent of the injected substance, which
in most studies was an anesthetic such as lidocaine,
bupivacaine, or procaine. No trials were of sufficient
quality or design to test the efficacy of any needling
technique beyond placebo in the treatment of myofascial
pain. In another systematic review with meta-analysis,
there was no significant difference between dry needling
and lidocaine in the management of MTrPs in the neck
and shoulder region. The quality of evidence for the
studies was limited [41].
In another study, TrP pain pressure values were sig-
nificantly higher in lidocaine group than dry needle and
pain scores were significantly lower than in both the
botulinum toxin type A (BTX-A) and dry needle groups.
The Canadian Agency for Drugs and Technologies for
Health (CADTH) conducted a Rapid Response and syn-
thesized evidence from identified one systematic review
and five RCTs. They concluded that evidence cannot
support the use of botulinum toxin type A (BoNTA) in-
jection in MTrPs for myofascial pain, given that four out
of five included trials reported that BoNTA had no sta-
tistically significant effect on pain. Therefore, BoNTA
was not considered to be effective for the treatment of
MPS [42]. In summary, there are few outcome studies of
good quality and, although some studies showed reduc-
tion in pain scores and pressure pain thresholds, the lit-
erature has neither convincingly supported nor refuted
the effectiveness of some invasive and non-invasive mo-
dalities beyond placebo [13].
Study limitations
There are a number of limitations of the present study. Be-
cause there were three different physical therapists who
conducted the PT intervention, it is possible that inter-
therapist effects may have influenced the findings. How-
ever the PT sessions were standardized via a protocol to
minimize this potential confounder. Similarly, there were
various medical specialists who performed the injections,
but all had more than 5 years of experience in the field
with MPS patients. Additionally, no validated functional
measure centered on the patient, such as the DASH, was
used. Future studies should include a validated measure of
function and a measure of the impact of the condition on
work performance, as well as an evaluation related to pa-
tient occupation and physical activity. In the current study,
patients were only followed for 3 months, and additional
research with longer follow-ups and a more comprehensive
evaluation of outcomes is needed to assess how much of
the improvement is maintained, the likelihood of relapses,
and the need for further consultation and treatment. Fi-
nally, it is known that studies of the efficacy of MTrPs in-
terventions have shown marked statistical heterogeneity
that make it is difficult to evaluate outcomes [43]. There-
fore, it is necessary to conduct further studies with a larger
number of patients so that analyses can examine different
subgroups of patients and determine if the interventions
might help to treat underlying pathologies, including spinal
conditions, postural abnormalities, and underlying behav-
ioral issues. Furthermore, it is important to include pa-
tients on a waiting list or in a sham treatment placebo
group in order to assess the superiority of one intervention
over another in this patient population [44].
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Conclusions
Myofascial pain is often chronic and treatment with any
of the interventions studied produced similar outcomes,
except for a slight advantage of those receiving interven-
tions with PT showing better right limb hand-back ma-
neuvering function compared to the LI only group.
These findings suggest that PT treatment involving the
use of hot packs and ultrasound, manual compression,
deep stroking or strumming, and muscle-stretching and
strengthening exercises could play a role in improving
upper limb function, although more research is needed.
Lidocaine injections, which produced similar outcomes
in the MPS patients studied, are an inexpensive treat-
ment even in repeated over time. Other studies have
found that botulinum toxin is no more effective than in-
jections with local anesthetic and is more expensive [42,
45–47]. Future research should examine more specific
PT treatments at varying time intervals, conduct longi-
tudinal assessment of more comprehensive longer-term
outcomes, assess and control for contextual factors like
the patient’s occupation, and incorporate additional out-
comes such as relapses and disability.
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